1 Introduction

Messenger RNA (mRNA) vaccines represent a groundbreaking advancement in the field of vaccinology, offering a promising alternative to traditional vaccine approaches. Unlike conventional vaccines, which often rely on inactivated pathogens or protein subunits, mRNA vaccines utilize synthetic mRNA to instruct cells to produce specific proteins that trigger an immune response. This innovative approach has several advantages, including high potency, rapid development, and the potential for low-cost manufacturing and safe administration (Pardi et al., 2018; Maruggi et al., 2019; Zhang et al., 2019). Recent technological advancements have significantly improved the stability and delivery efficiency of mRNA, making it a viable platform for both prophylactic and therapeutic vaccines (Pardi et al., 2018; Gote et al., 2023).

The concept of mRNA-based vaccines has been explored for over two decades, but it was not until recent years that significant progress was made in overcoming the challenges associated with mRNA instability and inefficient in vivo delivery (Pardi et al., 2018; Maruggi et al., 2019; Yang et al., 2022). The COVID-19 pandemic accelerated the development and approval of mRNA vaccines, with the Pfizer-BioNTech and Moderna vaccines becoming the first mRNA vaccines to receive emergency use authorization from regulatory agencies worldwide (Korang et al., 2022; Gote et al., 2023; Zhang, 2023). These vaccines have demonstrated high efficacy in preventing COVID-19 and have set a precedent for the rapid development and deployment of mRNA vaccines against other infectious diseases (Kim et al., 2021; Korang et al., 2022).

As mRNA vaccines continue to gain prominence, it is crucial to thoroughly evaluate their safety and effectiveness. Clinical trials and real-world data have shown that mRNA vaccines can induce potent and long-lasting immune responses with a favorable safety profile (Zhang et al., 2019; Jackson et al., 2020; Korang et al., 2022). However, ongoing monitoring and further research are necessary to fully understand the long-term safety and potential adverse effects of these vaccines (Korang et al., 2022). Evaluating the safety and efficacy of mRNA vaccines is essential to ensure public confidence and to guide future vaccine development efforts (Korang et al., 2022; Yang et al., 2022).

This study provides a comprehensive analysis of the safety and efficacy of mRNA vaccines by synthesizing data from clinical trials and real-world studies. By aggregating data from multiple sources, this study aims to understand in detail the benefits and potential risks of mRNA vaccines. The findings are significant for informing public health policies, guiding future research, and enhancing the development of next-generation mRNA vaccines. Additionally, this study contributes to the growing body of knowledge on mRNA vaccines and supports their continued advancement as a critical tool in combating infectious diseases.

2 Mechanism of mRNA Vaccines

2.1 How mRNA vaccines work

mRNA vaccines operate by utilizing messenger RNA to instruct cells to produce a protein that triggers an immune response. This process begins with the delivery of synthetic mRNA into the host cells, typically through lipid nanoparticles, which protect the mRNA from degradation and facilitate its entry into cells. Once inside, the mRNA is translated by the host's ribosomes to produce the target antigen, often a viral protein such as the spike protein of SARS-CoV-2. This antigen is then presented on the cell surface, where it is recognized by the immune system, prompting both humoral and cellular immune responses (Iavarone et al., 2017; Xu et al., 2020; Wang et al., 2021).

The immune response involves the activation of antigen-presenting cells, which process the antigen and present it to T cells, leading to the activation of B cells and the production of antibodies. This mechanism not only provides immediate protection but also establishes immunological memory, ensuring a rapid and robust response upon subsequent exposure to the pathogen (Iavarone et al., 2017; Wang et al., 2021). The ability to induce both arms of the adaptive immune system is a key feature of mRNA vaccines, contributing to their high efficacy.

2.2 Advantages of mRNA technology

One of the primary advantages of mRNA vaccine technology is its rapid development and production capabilities. Unlike traditional vaccines, which require the cultivation of live viruses or the production of protein subunits, mRNA vaccines can be synthesized quickly once the genetic sequence of the target antigen is known. This allows for a swift response to emerging infectious diseases, as demonstrated during the COVID-19 pandemic (Zhang et al., 2019; Jackson et al., 2020; Xu et al., 2020).

Additionally, mRNA vaccines are highly versatile and can be easily modified to target different pathogens or variants of a virus. This adaptability is complemented by their strong safety profile, as mRNA does not integrate into the host genome and is naturally degraded by cellular processes. Furthermore, advancements in mRNA stabilization and delivery systems have significantly improved the immunogenicity and efficacy of these vaccines, making them a promising platform for both infectious diseases and cancer immunotherapy (Alberer et al., 2017; Xu et al., 2020; Wang et al., 2021).

2.3 Challenges in mRNA vaccine development

Despite their advantages, mRNA vaccines face several challenges that need to be addressed to optimize their efficacy and widespread use. One major challenge is the inherent instability of mRNA, which requires careful formulation and storage conditions to maintain its integrity. Advances in lipid nanoparticle technology have mitigated some of these issues, but further improvements are necessary to enhance the stability and delivery of mRNA vaccines, especially in resource-limited settings (Figure 1) (Xu et al., 2020; Knezevic et al., 2021; Wang et al., 2021).

Wang et al. (2021) studied the main delivery methods for mRNA vaccines, including lipid-based delivery, polymer-based delivery, peptide-based delivery, virus-like replicon particles, cationic nanoemulsions, naked mRNA, and dendritic cell-based delivery. Among these, lipid nanoparticles and polymer nanoparticles protect mRNA from degradation by encapsulating it and facilitate cellular uptake. Each of these delivery methods has its own advantages and disadvantages, making them suitable for different application scenarios. The study indicates that optimizing delivery systems can significantly enhance the efficacy and stability of mRNA vaccines, promoting their use in disease prevention and treatment.

Real-world data also support the high efficacy of mRNA vaccines. A study involving healthcare personnel, first responders, and other essential workers found that the BNT162b2 and mRNA-1273 vaccines were 90% effective in preventing SARS-CoV-2 infection, regardless of symptom status (Thompson et al., 2020). This evidence highlights the robust protection offered by mRNA vaccines in both clinical trial settings and real-world conditions.

3.2 Comparison of efficacy across populations

The efficacy of mRNA vaccines has been consistent across different populations, including various age groups and individuals with comorbidities. For instance, the BNT162b2 vaccine has shown similar efficacy rates across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions (Polack et al., 2020). This broad efficacy profile suggests that mRNA vaccines are effective in diverse demographic groups.

However, some variations in efficacy have been observed in specific populations. For example, a study on the effectiveness of a third dose of mRNA vaccines found that vaccine efficacy against COVID-19-associated emergency department and urgent care encounters was lower during the Omicron variant predominance compared to the Delta variant period (Thompson et al., 2022). Despite these variations, the overall efficacy of mRNA vaccines remains high, particularly with the administration of booster doses, which significantly enhance protection (Ioannou et al., 2022; Thompson et al., 2022).

3.3 Long-term efficacy and booster doses

The long-term efficacy of mRNA vaccines has been a subject of ongoing research, particularly in the context of emerging variants and waning immunity. Studies have shown that vaccine-induced immunity can wane over time, necessitating booster doses to maintain high levels of protection. For instance, the effectiveness of mRNA vaccines against COVID-19-associated hospitalizations decreased over time but was significantly restored with a third (booster) dose (Ioannou et al., 2022; Thompson et al., 2022).

Booster doses have proven to be highly effective in enhancing immunity. A study on the effectiveness of a third dose of mRNA vaccines found that the booster dose increased vaccine efficacy against SARS-CoV-2 infection, hospitalization, and death, particularly during the Omicron variant era (Ioannou et al., 2022). Another study reported that a bivalent mRNA booster dose provided strong protection against COVID-19-associated hospitalization in older adults, further emphasizing the importance of booster doses in maintaining long-term efficacy (Surie et al., 2022).

4 Safety Profile of mRNA Vaccines

4.1 Short-term safety

The short-term safety profile of mRNA vaccines has been extensively studied across various clinical trials. In a phase 1 trial evaluating mRNA vaccines against H10N8 and H7N9 influenza viruses, the vaccines demonstrated favorable safety and reactogenicity profiles. No vaccine-related serious adverse events were reported, and the most common adverse reactions were mild to moderate, including pain at the injection site, headache, and fatigue (Feldman et al., 2019). Similarly, the mRNA-1273 SARS-CoV-2 vaccine showed an acceptable safety profile in a phase 2 trial, with the most common adverse reactions being pain at the injection site, headache, and fatigue. Only one serious adverse event, deemed unrelated to the vaccine, was reported (Chu et al., 2021).

Further supporting these findings, a phase 3 trial of the mRNA-1273 vaccine reported that moderate, transient reactogenicity occurred more frequently in the vaccine group compared to the placebo group. Serious adverse events were rare and occurred at similar rates in both groups (Baden et al., 2020). Another study on the BNT162b2 mRNA vaccine also reported a favorable safety profile, with the most common adverse events being mild to moderate pain at the injection site, fatigue, and headache (Thomas et al., 2021). These findings indicate that mRNA vaccines are generally well-tolerated in the short term, with most adverse events being mild and transient.

4.2 Long-term safety

Long-term safety data for mRNA vaccines are still being collected, but initial findings are promising. In a phase 3 trial of the mRNA-1273 vaccine, the median follow-up was 5.3 months, and no safety concerns were identified. The vaccine continued to be efficacious in preventing COVID-19 illness and severe disease, with an acceptable safety profile (Sahly et al., 2021). Similarly, the BNT162b2 vaccine showed a favorable safety profile through six months of follow-up, despite a gradual decline in vaccine efficacy. Serious adverse events were rare, and the incidence was similar between the vaccine and placebo groups (Thomas et al., 2021).

A systematic study and meta-analysis of COVID-19 mRNA vaccines in children aged 5 to 11 years also provided insights into long-term safety. The study found that while most children developed local adverse events, severe adverse events were rare and resolved within several days (Watanabe et al., 2023). Another study on the safety and immunogenicity of a mRNA rabies vaccine reported that the vaccine was generally safe with a reasonable tolerability profile, even one year after vaccination (Alberer et al., 2017). These findings suggest that mRNA vaccines have a favorable long-term safety profile, although continued monitoring is essential.

4.3 Safety in special populations

The safety of mRNA vaccines in special populations, such as immunocompromised individuals, has been a focus of recent research. A study investigating the BNT162b2 vaccine in five groups of immunocompromised patients found that the vaccine was generally safe, although the rate of seroconversion was substantially lower than in healthy controls (Figure 2). The study highlighted the need for additional vaccine doses in certain immunocompromised patient groups to improve immunity (Bergman et al., 2021). Another study on the mRNA-1273 vaccine included participants at high risk for SARS-CoV-2 infection or its complications. The vaccine showed 94.1% efficacy at preventing COVID-19 illness, including severe disease, with no safety concerns identified (Baden et al., 2020).

Bergman et al. (2021) studied the seroconversion and antibody titers in different immunocompromised patient groups and healthy controls. The study indicated that the seroconversion rate and antibody titers post-vaccination were significantly higher in the healthy control group compared to the immunocompromised groups. Among the immunocompromised patients, those in the HIV and HSCT/CAR-T groups showed more notable antibody responses, while the SOT and CLL groups exhibited weaker responses. These results highlight the differential responses to vaccination among immunocompromised patients, suggesting the need for personalized vaccination strategies to enhance protection in these high-risk populations.

In children aged 5 to 11 years, a systematic study and meta-analysis found that mRNA COVID-19 vaccines were associated with lower risks of SARS-CoV-2 infections and severe COVID-19-related illnesses. Most vaccinated children experienced at least one local adverse event, but severe adverse events were rare and resolved within several days (Watanabe et al., 2023). These findings indicate that mRNA vaccines are generally safe in special populations, although additional doses or tailored vaccination strategies may be necessary for optimal protection.

5 Comparative Analysis

5.1 mRNA vaccines vs. traditional vaccines

mRNA vaccines, such as those developed for COVID-19, represent a novel approach compared to traditional vaccines like inactivated or live attenuated vaccines. Traditional vaccines, such as the inactivated hepatitis A vaccine (HA-I) and live attenuated hepatitis A vaccine (HA-L), have been shown to provide robust immunogenicity and safety profiles in various populations. For instance, a study comparing HA-I and HA-L in Chinese children demonstrated high seroconversion rates and acceptable safety profiles for both vaccines, with HA-I showing slightly higher geometric mean concentrations of antibodies after a booster dose (Ma et al., 2016). Similarly, inactivated influenza vaccines have been shown to provide broad protection against circulating influenza viruses with minimal adverse reactions (Wang et al., 2021).

In contrast, mRNA vaccines have shown a higher efficacy in preventing SARS-CoV-2 infection compared to traditional vaccines. A systematic study and meta-analysis indicated that mRNA vaccines conferred a significantly lower risk of SARS-CoV-2 infection compared to viral vector and inactivated vaccines (Fan et al., 2021). However, mRNA vaccines were also associated with a higher incidence of certain adverse events, such as serious vessel disorders, compared to traditional vaccines (Fan et al., 2021). Despite these differences, both mRNA and traditional vaccines have demonstrated the ability to induce strong immune responses and provide protection against their respective target pathogens.

5.2 Comparison with other COVID-19 vaccines

When comparing mRNA vaccines to other COVID-19 vaccines, such as inactivated and viral vector vaccines, several key differences emerge. Inactivated vaccines like CoronaVac and BBIBP-CorV have shown good safety profiles and moderate efficacy in preventing symptomatic COVID-19. For example, the CoronaVac vaccine demonstrated an efficacy of 83.5% in preventing PCR-confirmed symptomatic COVID-19 in a phase 3 trial in Turkey, with a good safety profile (Tanriover et al., 2021). Similarly, the BBIBP-CorV vaccine was found to be safe and well-tolerated, inducing strong humoral responses in both younger and older adults (Xia et al., 2020; Wu et al., 2021).

However, mRNA vaccines, such as BNT162b2 and mRNA-1273, have shown higher efficacy rates in preventing COVID-19 infection and severe outcomes. A comparative study found that mRNA vaccines elicited higher antibody and neutralization titers compared to the Ad26.COV2.S viral vector vaccine, and were more effective in preventing infection, hospitalization, and death (Naranbhai et al., 2021). Additionally, a meta-analysis reported that mRNA vaccines had an efficacy of 85% in participants aged 18 years and older, compared to 73% for adenovirus vector vaccines (Sharif et al., 2021). These findings highlight the superior efficacy of mRNA vaccines in the context of COVID-19, although the safety profiles of different vaccine platforms remain an important consideration.

5.3 Advantages and disadvantages

mRNA vaccines offer several advantages over traditional and other COVID-19 vaccines. One of the primary advantages is their high efficacy in preventing SARS-CoV-2 infection and severe disease outcomes. Studies have shown that mRNA vaccines, such as BNT162b2 and mRNA-1273, provide robust immune responses and high levels of protection against COVID-19 (Naranbhai et al., 2021; Sharif et al., 2021). Additionally, mRNA vaccines can be rapidly developed and manufactured, allowing for a swift response to emerging infectious diseases (Alberer et al., 2017).

However, mRNA vaccines also have some disadvantages. They are associated with a higher incidence of certain adverse events, such as serious vessel disorders, compared to traditional vaccines (Fan et al., 2021). Additionally, mRNA vaccines require stringent cold chain storage conditions, which can pose logistical challenges, particularly in low-resource settings (Alberer et al., 2017). In contrast, traditional vaccines, such as inactivated and live attenuated vaccines, often have more established safety profiles and less demanding storage requirements, making them more accessible in various settings (Ma et al., 2016; Wang et al., 2021).

6 Case Study

6.1 Case study 1: pfizer-BioNTech (BNT162b2) vaccine

The Pfizer-BioNTech (BNT162b2) vaccine has demonstrated significant efficacy and safety in various clinical trials and real-world studies. In a pivotal efficacy trial involving 43,448 participants, the BNT162b2 vaccine showed a 95% efficacy in preventing COVID-19 among individuals aged 16 years and older. The trial reported that the vaccine was effective across different subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. The safety profile was characterized by mild-to-moderate pain at the injection site, fatigue, and headache, with a low incidence of serious adverse events (Figure 3) (Polack et al., 2020). Further studies extended the follow-up period to six months, confirming the vaccine's continued efficacy at 91.3% and a favorable safety profile, although a gradual decline in efficacy was noted over time (Thomas et al., 2021).

Figure 3 Local and Systemic Reactions After BNT162b2 Vaccination in Different Age Groups (Adapted from Polack et al., 2020)

Real-world data also support the vaccine's effectiveness. For instance, a study conducted by the VISION Network across 10 states in the U.S. found that the vaccine was highly effective in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among children and adolescents aged 5-17 years. The vaccine efficacy (VE) was particularly high among adolescents aged 12-17 years, with VE increasing to 86% after a third booster dose during the Omicron predominant period (Klein et al., 2022). Additionally, the vaccine was shown to be 93% effective in preventing COVID-19 hospitalization among adolescents aged 12-18 years during the Delta variant predominance (Olson et al, 2021). These findings underscore the importance of vaccination in controlling the pandemic and protecting various age groups from severe outcomes.

6.2 Case study 2: moderna (mRNA-1273) vaccine

The Moderna (mRNA-1273) vaccine has also shown high efficacy and safety in clinical trials and real-world settings. In a study involving healthcare personnel, first responders, and other essential workers, the mRNA-1273 vaccine demonstrated a 90% effectiveness in preventing SARS-CoV-2 infection, regardless of symptom status. This study highlighted the vaccine's benefits in real-world conditions, emphasizing its role in protecting working-age adults (Thompson et al., 2021). Another comparative study found that the Moderna vaccine had a higher vaccine effectiveness (93%) against COVID-19 hospitalizations compared to the Pfizer-BioNTech vaccine (88%) among adults without immunocompromising conditions (Self et al., 2021).

Further research has shown that a third dose of the Moderna vaccine significantly improves protection against COVID-19-associated hospitalization. Among immunocompetent adults, the vaccine effectiveness was 97% for those who received a booster dose compared to 82% for those who received only two doses. Similarly, among adults with immunocompromising conditions, the effectiveness was 88% for those who received a third dose compared to 69% for two-dose recipients (Tenforde et al., 2022). These findings highlight the importance of booster doses in maintaining high levels of protection, especially among vulnerable populations.

6.3 Case study 3: mRNA rabies vaccine (CV7201)

The mRNA rabies vaccine (CV7201) represents a novel approach to rabies immunization, leveraging the same mRNA technology used in COVID-19 vaccines. Although specific data on CV7201 were not provided in the abstracts, the general principles of mRNA vaccine technology suggest that CV7201 would likely exhibit similar safety and immunogenicity profiles. mRNA vaccines work by encoding the antigen of interest, in this case, the rabies virus glycoprotein, which is then translated by the host cells to elicit an immune response.

The success of mRNA vaccines like BNT162b2 and mRNA-1273 in preventing COVID-19 provides a strong foundation for the development of other mRNA-based vaccines, including CV7201. The ability to rapidly design and produce mRNA vaccines, coupled with their robust immune responses and favorable safety profiles, makes them a promising platform for addressing various infectious diseases. Future studies will be essential to evaluate the specific efficacy and safety of CV7201 in clinical trials, but the existing data on mRNA vaccine technology are encouraging and suggest a high potential for success.

7 Challenges and Limitations

7.1 Manufacturing and distribution

The manufacturing and distribution of mRNA vaccines present significant challenges that need to be addressed to ensure their widespread availability and efficacy. One of the primary challenges is the complexity of the manufacturing process, which involves multiple steps such as in vitro transcription, purification, and formulation. These steps require sophisticated technology and stringent quality control measures to ensure the production of high-quality mRNA vaccines. Additionally, the scalability of the manufacturing process is a critical issue. Large-scale production demands a cost-effective and efficient platform, which is currently a bottleneck in the rapid deployment of mRNA vaccines (Pardi et al., 2020; Rosa et al., 2021; Gote et al., 2023).

Another major challenge in the distribution of mRNA vaccines is the requirement for ultra-cold storage conditions. mRNA vaccines, such as those developed for COVID-19, need to be stored at extremely low temperatures to maintain their stability and efficacy. This necessitates a robust cold chain infrastructure, which is not readily available in many parts of the world, particularly in low- and middle-income countries. The logistical complexities of maintaining such a cold chain can hinder the timely and equitable distribution of mRNA vaccines, thereby limiting their global impact (Knezevic et al., 2021; Rosa et al., 2021; Chen et al., 2022).

7.2 Public perception and vaccine hesitancy

Public perception and vaccine hesitancy are significant barriers to the successful deployment of mRNA vaccines. Despite the demonstrated efficacy and safety of mRNA vaccines in clinical trials, misinformation and skepticism about their rapid development and novel technology have led to public distrust. Concerns about potential side effects, such as allergic reactions and long-term health impacts, contribute to vaccine hesitancy. Addressing these concerns through transparent communication and public education is crucial to improving vaccine uptake (Zhang et al., 2019; Liang et al., 2021; Wang et al., 2021).

Moreover, the rapid development and emergency use authorization of mRNA vaccines during the COVID-19 pandemic have fueled conspiracy theories and misinformation, further exacerbating vaccine hesitancy. Social media platforms have played a significant role in spreading false information, making it challenging to build public trust. Efforts to combat misinformation and promote accurate information about the benefits and safety of mRNA vaccines are essential to overcoming public perception issues and ensuring widespread acceptance (Maruggi et al., 2019; Knezevic et al., 2021; Chen et al., 2022).

7.3 Limitations in current data

The current data on mRNA vaccines, while promising, have several limitations that need to be addressed through ongoing research and long-term studies. One of the primary limitations is the lack of long-term safety and efficacy data. Most of the available data are from short-term clinical trials, and the long-term effects of mRNA vaccines are still unknown. This uncertainty can affect public confidence and regulatory decisions regarding the widespread use of these vaccines (Pardi et al., 2020; Kim et al., 2021; Gote et al., 2023).

Additionally, there is limited data on the efficacy of mRNA vaccines in diverse populations, including different age groups, ethnicities, and individuals with underlying health conditions. Ensuring that mRNA vaccines are effective and safe for all segments of the population requires comprehensive and inclusive clinical trials. Furthermore, the potential for rare adverse events, which may not be detected in initial trials, underscores the need for robust post-marketing surveillance to monitor the long-term safety of mRNA vaccines (Maruggi et al., 2019; Zhang et al., 2019; Wang et al., 2021).

8 Future Directions

8.1 Next-generation mRNA vaccines

The development of next-generation mRNA vaccines is poised to revolutionize the field of vaccinology. Recent advancements have demonstrated the potential of mRNA vaccines to combat a wide range of infectious diseases and cancers, where traditional vaccine platforms have often fallen short (Pardi et al., 2018; Pardi et al., 2020). Innovations in mRNA delivery systems, such as lipid nanoparticles (LNPs), have significantly improved the stability and efficiency of mRNA vaccines, making them more viable for widespread use (Liang et al., 2021; Gote et al., 2023). These advancements have not only enhanced the immunogenicity of mRNA vaccines but also reduced the risk of adverse effects, thereby improving their safety profile (Schlake et al., 2012; Feldman et al., 2019).

Future research is likely to focus on optimizing the molecular design of mRNA vaccines to further enhance their efficacy and safety. This includes the development of self-amplifying mRNA vaccines, which can produce more antigen per dose, thereby requiring lower amounts of mRNA and potentially reducing side effects (Kim et al., 2021). Additionally, the exploration of novel delivery systems and routes of administration will be crucial in overcoming current limitations, such as rapid mRNA degradation and the risk of cytokine storms (Iavarone et al., 2017; Liang et al., 2021). These efforts will pave the way for the next generation of mRNA vaccines, offering more effective and safer options for preventing and treating a variety of diseases.

8.2 Ongoing and future research

Ongoing research in the field of mRNA vaccines is focused on expanding their applications beyond infectious diseases to include personalized cancer vaccines. Clinical trials have shown promising results, with mRNA vaccines inducing robust immune responses in both animal models and humans (Maruggi et al., 2019; Zhang et al., 2019). These vaccines can be rapidly designed and manufactured, making them ideal for responding to emerging infectious diseases and personalized medicine (Pardi et al., 2018; Gote et al., 2023). The flexibility of mRNA technology allows for the quick adaptation of vaccine formulations to target new pathogens or tumor antigens, which is a significant advantage over traditional vaccine platforms (Schlake et al., 2012; Feldman et al., 2019).

Future research will likely explore the combination of mRNA vaccines with other therapeutic modalities, such as checkpoint inhibitors and other immunotherapies, to enhance their efficacy in cancer treatment (Maruggi et al., 2019; Pardi et al., 2020). Additionally, efforts will be made to improve the scalability and cost-effectiveness of mRNA vaccine production, making them more accessible to low- and middle-income countries (Liang et al., 2021; Gote et al., 2023). The integration of advanced bioinformatics and machine learning techniques will also play a crucial role in optimizing vaccine design and predicting immune responses, thereby accelerating the development of more effective mRNA vaccines (Iavarone et al., 2017; Kim et al., 2021).

8.3 Addressing current challenges

Despite the significant progress made in mRNA vaccine technology, several challenges remain that need to be addressed to fully realize their potential. One of the primary challenges is the stability of mRNA, which can be rapidly degraded in the body, reducing the effectiveness of the vaccine (Pardi et al., 2018; Liang et al., 2021). Advances in delivery systems, such as the use of lipid nanoparticles and other biocompatible carriers, have shown promise in protecting mRNA from degradation and enhancing its delivery to target cells (Feldman et al., 2019; Gote et al., 2023). However, further research is needed to optimize these delivery systems and ensure consistent and efficient mRNA expression in vivo (Schlake et al., 2012; Iavarone et al., 2017).

Another challenge is the potential for adverse immune reactions, such as cytokine storms, which can pose significant risks to vaccine recipients (Kim et al., 2021; Liang et al., 2021). Understanding the mechanisms of action of mRNA vaccines and their interactions with the immune system is crucial for mitigating these risks (Iavarone et al., 2017). Additionally, addressing the logistical challenges of mRNA vaccine storage and distribution, particularly in resource-limited settings, will be essential for their global deployment (Feldman et al., 2019; Maruggi et al., 2019). By tackling these challenges through continued research and innovation, the full potential of mRNA vaccines can be harnessed to improve public health outcomes worldwide.

9 Concluding Remarks

The systematic study of clinical trials on mRNA vaccines, particularly mRNA-1273 and BNT162b2, has demonstrated significant efficacy and safety in preventing COVID-19 across diverse populations. The mRNA-1273 vaccine showed an efficacy of 94.1% in preventing symptomatic COVID-19 and 98.2% in preventing severe disease, with no major safety concerns identified. Similarly, the BNT162b2 vaccine exhibited a 95% efficacy in preventing COVID-19 and a 96.7% efficacy against severe disease, maintaining a favorable safety profile over six months. In children aged 5 to 11 years, mRNA vaccines were associated with reduced risks of SARS-CoV-2 infection and severe COVID-19-related illnesses, with most adverse events being mild and transient. Additionally, mRNA vaccines have shown robust immunogenicity and acceptable safety profiles in various age groups and among immunocompromised patients, although the latter group exhibited lower seroconversion rates.

The high efficacy and acceptable safety profiles of mRNA vaccines underscore their critical role in controlling the COVID-19 pandemic. The ability of these vaccines to prevent both symptomatic and severe disease across different demographic groups, including children and immunocompromised individuals, highlights their broad applicability and importance in achieving herd immunity. The findings support the continued use and expansion of mRNA vaccination programs globally, particularly in high-risk populations. Moreover, the data suggest that additional doses or booster shots may be necessary for certain immunocompromised groups to enhance their immune response. Public health strategies should also focus on addressing vaccine hesitancy by communicating the robust safety and efficacy data to the public.

The development and deployment of mRNA vaccines represent a significant scientific achievement in the fight against COVID-19. The evidence from clinical trials indicates that these vaccines are not only effective in preventing infection and severe disease but also safe for widespread use. Continued monitoring and research are essential to understand the long-term efficacy and safety of these vaccines, especially in the context of emerging variants. Future studies should also explore the optimal vaccination strategies for immunocompromised individuals and other vulnerable populations. Overall, mRNA vaccines have proven to be a pivotal tool in mitigating the impact of the COVID-19 pandemic and will likely play a crucial role in managing future infectious disease outbreaks.

Acknowledgments

Thanks to the anonymous peer reviewers for their comments on the manuscript.

Conflict of Interest Disclosure

The authors affirm that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Alberer M., Gnad-Vogt U., Hong H., Mehr K., Backert L., Finak G., Gottardo R., Bica M., Garofano A., Koch S., Fotin‐Mleczek M., Hoerr I., Clemens R., and Sonnenburg F., 2017, Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial, The Lancet, 390: 1511-1520.

https://doi.org/10.1016/S0140-6736(17)31665-3

PMid:28754494

Baden L., Sahly H., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S., Rouphael N., Creech C., Mcgettigan J., Kehtan S., Segall N., Solis J., Brosz A., Fierro C., Schwartz H., Neuzil K., Corey L., Gilbert P., Janes H., Follmann D., Marovich M., Mascola J., Polakowski L., Ledgerwood J., Graham B., Bennett H., Pajon R., Knightly C., Leav B., Deng W., Zhou H., Han S., Ivarsson M., Miller J., and Zaks T., 2020, Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine, The New England Journal of Medicine, 384(5): 403-416.

https://doi.org/10.1056/NEJMoa2035389

PMid:33378609 PMCid:PMC7787219

Bergman P., Blennow O., Hansson L., Mielke S., Nowak P., Chen P., Söderdahl G., Österborg A., Smith C., Wullimann D., Vesterbacka J., Lindgren G., Blixt L., Friman G., Wahren-Borgström E., Nordlander A., Gomez A., Akber M., Valentini D., Norlin A., Thalme A., Bogdanovic G., Muschiol S., Nilsson P., Hober S., Loré K., Chen M., Buggert M., Ljunggren H., Ljungman P., and Aleman S., 2021, Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial, EBioMedicine, 74: 103705.

https://doi.org/10.1016/j.ebiom.2021.103705.

PMid:34861491 PMCid:PMC8629680

Chen J., Chen J., and Xu Q., 2022, Current developments and challenges of mRNA vaccines., Annual Review of Biomedical Engineering, 24: 85-109.

https://doi.org/10.1146/annurev-bioeng-110220-031722

PMid:35231177

Chu L., McPhee R., Huang W., Bennett H., Pajon R., Nestorova B., and Leav B., 2021, A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine, Vaccine, 39: 2791-2799.

https://doi.org/10.1016/j.vaccine.2021.02.007

PMid:33707061 PMCid:PMC7871769

Fan Y., Chan K., and Hung I., 2021, Safety and efficacy of COVID-19 vaccines: a systematic review and meta-analysis of different vaccines at phase 3, Vaccines, 9(9): 989.

https://doi.org/10.3390/vaccines9090989.

PMid:34579226 PMCid:PMC8473448

Feldman R., Fuhr R., Smolenov I., Ribeiro A., Panther L., Watson M., Senn J., Smith M., Almarsson Ӧ., Pujar H., Laska M., Thompson J., Zaks T., and Ciaramella G., 2019, mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials, Vaccine, 37: 3326-3334.

https://doi.org/10.1016/j.vaccine.2019.04.074

PMid:31079849

Gote V., Bolla P., Kommineni N., Butreddy A., Nukala P., Palakurthi S., and Khan W., 2023, A comprehensive review of mRNA vaccines, International Journal of Molecular Sciences, 24(3): 2700.

https://doi.org/10.3390/ijms24032700

PMid:36769023 PMCid:PMC9917162

Graña C., Ghosn L., Evrenoglou T., Jarde A., Minozzi S., Bergman H., Buckley B., Probyn K., Villanueva G., Henschke N., Bonnet H., Assi R., Menon S., Marti M., Devane D., Mallon P., Lelièvre J., Askie L., Kredo T., Ferrand G., Davidson M., Riveros C., Tovey D., Meerpohl J., Grasselli G., Rada G., Hrõbjartsson A., Ravaud P., Chaimani A., and Boutron I., 2022, Efficacy and safety of COVID‐19 vaccines, The Cochrane Database of Systematic Reviews, 12(12): CD015477.

https://doi.org/10.1002/14651858.CD015477

PMid:36473651 PMCid:PMC9726273

Iavarone C., O'hagan D., Yu D., Delahaye N., and Ulmer J., 2017, Mechanism of action of mRNA-based vaccines, Expert Review of Vaccines, 16: 871-881.

https://doi.org/10.1080/14760584.2017.1355245

PMid:28701102

Ioannou G., Bohnert A., O'Hare A., Boyko E., Maciejewski M., Smith V., Bowling C., Viglianti E., Iwashyna T., Hynes D., Berry K., Green P., Fox A., Korpak A., Shahoumian T., Hickok A., Rowneki M., Wang X., and Locke E., 2022, Effectiveness of mRNA COVID-19 vaccine boosters against infection, hospitalization, and death: a target trial emulation in the omicron (B.1.1.529) variant era, Annals of Internal Medicine, 175(12): 1693-1706.

https://doi.org/10.7326/M22-1856

PMid:36215715 PMCid:PMC9575390

Jackson N., Kester K., Casimiro D., Gurunathan S., and Derosa F., 2020, The promise of mRNA vaccines: a biotech and industrial perspective, NPJ Vaccines, 5: 11.

https://doi.org/10.1038/s41541-020-0159-8

PMid:32047656 PMCid:PMC7000814

Kim J., Eygeris Y., Gupta M., and Sahay G., 2021, Self-assembled mRNA vaccines, Advanced Drug Delivery Reviews, 170: 83-112.

https://doi.org/10.1016/j.addr.2020.12.014

PMid:33400957 PMCid:PMC7837307

Klein N., Stockwell M., Demarco M., Gaglani M., Kharbanda A., Irving S., Rao S., Grannis S., Dascomb K., Murthy K., Rowley E., Dalton A., DeSilva M., Dixon B., Natarajan K., Stenehjem E., Naleway A., Lewis N., Ong T., Patel P., Konatham D., Embí P., Reese S., Han J., Grisel N., Goddard K., Barron M., Dickerson M., Liao I., Fadel W., Yang D., Arndorfer J., Fireman B., Griggs E., Valvi N., Hallowell C., Zerbo O., Reynolds S., Ferdinands J., Wondimu M., Williams J., Bozio C., Link-Gelles R., Azziz‐Baumgartner E., Schrag S., Thompson M., and Verani J., 2022, Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 Years - VISION Network, 10 states, April 2021-January 2022, Morbidity and Mortality Weekly Report, 71: 352-358.

https://doi.org/10.15585/mmwr.mm7109e3

PMid:35239634 PMCid:pmc8893336

Knezevic I., Liu M., Peden K., Zhou T., and Kang H., 2021, Development of mRNA vaccines: scientific and regulatory issues, Vaccines, 9(2): 81.

https://doi.org/10.3390/vaccines9020081

PMid:33498787 PMCid:PMC7910833

Korang S., Rohden E., Veroniki A., Ong G., Ngalamika O., Siddiqui F., Juul S., Nielsen E., Feinberg J., Petersen J., Legart C., Kokogho A., Maagaard M., Klingenberg S., Thabane L., Bardach A., Ciapponi A., Thomsen A., Jakobsen J., and Gluud C., 2022, Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials, PLoS ONE, 39(17): 3845-3852.

https://doi.org/10.1371/journal.pone.0260733

PMid:35061702 PMCid:PMC8782520

Liang Y., Huang L., and Liu T., 2021, Development and delivery systems of mRNA vaccines, Frontiers in Bioengineering and Biotechnology, 9: 718753.

https://doi.org/10.3389/fbioe.2021.718753

PMid:34386486 PMCid:PMC8354200

Ma F., Yang J., Kang G., Sun Q., Lu P., Zhao Y., Wang Z., Luo J., and Wang Z., 2016, Comparison of the safety and immunogenicity of live attenuated and inactivated hepatitis A vaccine in healthy Chinese children aged 18 months to 16 years: results from a randomized, parallel controlled, phase IV study., Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 22(9): 811.e9-811.e15.

https://doi.org/10.1016/j.cmi.2016.06.004

PMid:27345175

Maruggi G., Zhang C., Li J., Ulmer J., and Yu D., 2019, mRNA as a transformative technology for vaccine development to control infectious diseases., Molecular therapy : the journal of the American Society of Gene Therapy, 27(4): 757-772.

https://doi.org/10.1016/j.ymthe.2019.01.020

PMid:30803823 PMCid:PMC6453507

Naranbhai V., García-Beltrán W., Chang C., Mairena C., Thierauf J., Kirkpatrick G., Onozato M., Cheng J., Denis K., Lam E., Kaseke C., Tano-Menka R., Yang D., Pavlovic M., Yang W., Kui A., Miller T., Astudillo M., Cahill J., Dighe A., Gregory D., Poznansky M., Gaiha G., Balazs A., and Iafrate A., 2021, Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 vaccines, The Journal of Infectious Diseases, 225: 1141-1150.

https://doi.org/10.1093/infdis/jiab593

PMid:34888672 PMCid:PMC8689763

Olson S., Newhams M., Halasa N., Price A., Boom J., Sahni L., Irby K., Walker T., Schwartz S., Pannaraj P., Maddux A., Bradford T., Nofziger R., Boutselis B., Cullimore M., Mack E., Schuster J., Gertz S., Cvijanovich N., Kong M., Cameron M., Staat M., Levy E., Chatani B., Chiotos K., Zambrano L., Campbell A., Patel M., and Randolph A., 2021, Effectiveness of pfizer-BioNTech mRNA vaccination against COVID-19 hospitalization among persons aged 12-18 years-united states, june-september 2021., MMWR, Morbidity and mortality weekly report, 70(42): 1483-1488.

https://doi.org/10.15585/mmwr.mm7042e1

PMid:34673751 PMCid:PMC9361838

Pardi N., Hogan M., Porter F., and Weissman D., 2018, mRNA vaccines - a new era in vaccinology, Nature Reviews Drug Discovery, 17: 261-279.

https://doi.org/10.1038/nrd.2017.243

PMid:29326426 PMCid:PMC5906799

Pardi N., Hogan M., and Weissman D., 2020, Recent advances in mRNA vaccine technology, Current opinion in immunology, 65: 14-20.

https://doi.org/10.1016/j.coi.2020.01.008

PMid:32244193

Polack F., Thomas S., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J., Marc G., Moreira E., Zerbini C., Bailey R., Swanson K., Roychoudhury S., Koury K., Li P., Kalina W., Cooper D., Frenck R., Hammitt L., Türeci Ö., Nell H., Schaefer A., Ünal S., Tresnan D., Mather S., Dormitzer P., Şahin U., Jansen K., and Gruber W., 2020, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, The New England Journal of Medicine, 383: 2603-2615.

https://doi.org/10.1056/NEJMoa2034577

PMid:33301246 PMCid:PMC7745181

Rosa S., Prazeres D., Azevedo A., and Marques M., 2021, mRNA vaccines manufacturing: challenges and bottlenecks, Vaccine, 39: 2190-2200.

https://doi.org/10.1016/j.vaccine.2021.03.038

PMid:33771389 PMCid:PMC7987532

Sahly H., Baden L., Essink B., Doblecki-Lewis S., Martin J., Anderson E., Campbell T., Clark J., Jackson L., Fichtenbaum C., Zervos M., Rankin B., Eder F., Feldman G., Kennelly C., Han-Conrad L., Levin M., Neuzil K., Corey L., Gilbert P., Janes H., Follmann D., Marovich M., Polakowski L., Mascola J., Ledgerwood J., Graham B., August A., Clouting H., Deng W., Han S., Leav B., Manzo D., Pajon R., Schödel F., Tomassini J., Zhou H., and Miller J., 2021, Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase, The New England Journal of Medicine, 385: 1774-1785.

https://doi.org/10.1056/NEJMoa2113017

PMid:34551225 PMCid:PMC8482810

Self W., Tenforde M., Rhoads J., Gaglani M., Ginde A., Douin D., Olson S., Talbot H., Casey J., Mohr N., Zepeski A., McNeal T., Ghamande S., Gibbs K., Files D., Hager D., Shehu A., Prekker M., Erickson H., Gong M., Mohamed A., Henning D., Steingrub J., Peltan I., Brown S., Martin E., Monto A., Khan A., Hough C., Busse L., Lohuis C., Duggal A., Wilson J., Gordon A., Qadir N., Chang S., Mallow C., Rivas C., Babcock H., Kwon J., Exline M., Halasa N., Chappell J., Lauring A., Grijalva C., Rice T., Jones I., Stubblefield W., Baughman A., Womack K., Lindsell C., Hart K., Zhu Y., Mills L., Lester S., Stumpf M., Naioti E., Kobayashi M., Verani J., Thornburg N., Patel M., Calhoun N., Murthy K., Herrick J., McKillop A., Hoffman E., Zayed M., Smith M., Seattle N., Ettlinger J., Priest E., Thomas J., Arroliga A., Beeram M., Kindle R., Kozikowski L., Souza L., Ouellette S., Thornton-Thompson S., Mehkri O., Ashok K., Gole S., King A., Poynter B., Stanley N., Hendrickson A., Maruggi E., Scharber T., Jorgensen J., Bowers R., King J., Aston V., Armbruster B., Rothman R., Nair R., Chen J., Karow S., Robart E., Maldonado P., Khan M., So P., Levitt J., Perez C., Visweswaran A., Roque J., Rivera A., Angeles L., Frankel T., Goff J., Huynh D., Howell M., Friedel J., Tozier M., Driver C., Carricato M., Foster A., Nassar P., Stout L., Sibenaller Z., Walter A., Marés J., Olson L., Clinansmith B., Rivas C., Gershengorn H., McSpadden E., Truscon R., Kaniclides A., Thomas L., Bielak R., Valvano W., Fong R., Fitzsimmons W., Blair C., Valesano A., Gilbert J., Crider C., Steinbock K., Paulson T., Anderson L., Kampe C., Johnson J., Mchenry R., Blair M., Conway D., LaRose M., Landreth L., Hicks M., Parks L., Bongu J., Mcdonald D., Cass C., Seiler S., Park D., Hink T., Wallace M., Burnham C., and Arter O., 2021, Comparative effectiveness of moderna, pfizer-bionTech, and janssen (johnson & johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions - united states, march-august 2021, Morbidity and Mortality Weekly Report, 70: 1337-1343.

https://doi.org/10.15585/mmwr.mm7038e1

PMid:34555004 PMCid:PMC8459899

Schlake T., Thess A., Fotin‐Mleczek M., and Kallen K., 2012, Developing mRNA-vaccine technologies, RNA Biology, 9: 1319-1330.

https://doi.org/10.4161/rna.22269

PMid:23064118 PMCid:PMC3597572

Sharif N., Alzahrani K., Ahmed S., and Dey S., 2021, Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis, Frontiers in Immunology, 12: 714170.

https://doi.org/10.3389/fimmu.2021.714170

PMid:34707602 PMCid:PMC8542872

Surie D., DeCuir J., Zhu Y., Gaglani M., Ginde A., Douin D., Talbot H., Casey J., Mohr N., Zepeski A., McNeal T., Ghamande S., Gibbs K., Files D., Hager D., Ali H., Taghizadeh L., Gong M., Mohamed A., Johnson N., Steingrub J., Peltan I., Brown S., Martin E., Khan A., Bender W., Duggal A., Wilson J., Qadir N., Chang S., Mallow C., Kwon J., Exline M., Lauring A., Shapiro N., Columbus C., Halasa N., Chappell J., Grijalva C., Rice T., Stubblefield W., Baughman A., Womack K., Rhoads J., Hart K., Swan S., Lewis N., McMorrow M., and Self W., 2022, Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated hospitalization among immunocompetent adults aged ≥65 Years - IVY network, 18 states, september 8-november 30, 2022, Morbidity and Mortality Weekly Report, 71: 1625-1630.

https://doi.org/10.15585/mmwr.mm715152e2

PMid:36580424 PMCid:PMC9812444

Tanriover M., Doğanay H., Akova M., Güner H., Azap A., Akhan S., Köse Ş., Erdinc F., Akalın E., Tabak Ö., Pullukçu H., Batum Ö., YAVUZ S., Turhan Ö., Yıldırmak M., Köksal İ., Taşova Y., Korten V., Yılmaz G., Çelen M., Altın S., Çelik I., Bayindir Y., Karaoğlan I., Yılmaz A., Özkul A., Gür H., Unal S., Akdemir-K B., Kayaaslan B., Hasanoğlu I., Dalkıran A., Aydos Ö., Cınar G., Akdemir-Kalkan I., Inkaya A., Aydın M., Çakir H., Yıldız J., Kocabıyık Ö., Arslan S., Nallı B., Demir Ö., Singil S., Ataman-Hatipoglu C., Tuncer-Ertem G., Kınıklı S., Önal U., Mete B., Dalgan G., Taşbakan M., Yamazhan T., Kömürcüoğlu B., Yalnız E., Benli A., Keskin-Sarıtaş Ç., Ertosun M., Özkan Ö., Emre S., Arıca S., Kuşçu F., Candevir A., Ertürk-Sengel B., Ayvaz F., Aksoy F., Mermutluoğlu Ç., Demir Y., Günlüoğlu G., Tural-Önür S., Kılıç-Toker A., Eren E., Otlu B., Mete A., Koçak K., Ateş H., Koca-Kalkan İ., and Aksu K., 2021, Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey, Lancet (London, England), 398: 213-222.

https://doi.org/10.1016/S0140-6736(21)01429-X

PMid:34246358

Tenforde M., Patel M., Gaglani M., Ginde A., Douin D., Talbot H., Casey J., Mohr N., Zepeski A., McNeal T., Ghamande S., Gibbs K., Files D., Hager D., Shehu A., Prekker M., Erickson H., Gong M., Mohamed A., Johnson N., Srinivasan V., Steingrub J., Peltan I., Brown S., Martin E., Monto A., Khan A., Hough C., Busse L., Duggal A., Wilson J., Qadir N., Chang S., Mallow C., Rivas C., Babcock H., Kwon J., Exline M., Botros M., Lauring A., Shapiro N., Halasa N., Chappell J., Grijalva C., Rice T., Jones I., Stubblefield W., Baughman A., Womack K., Rhoads J., Lindsell C., Hart K., Zhu Y., Naioti E., Adams K., Lewis N., Surie D., McMorrow M., and Self W., 2022, Effectiveness of a third dose of Pfizer-BioNTech and moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults - United States, August-December 2021, Morbidity and Mortality Weekly Report, 71: 118-124.

https://doi.org/10.15585/mmwr.mm7104a2

PMid:35085218 PMCid:PMC9351530

Thompson M., Burgess J., Naleway A., Tyner H., Yoon S., Meece J., Olsho L., Caban-Martinez A., Fowlkes A., Lutrick K., Kuntz J., Dunnigan K., Odean M., Hegmann K., Stefanski E., Edwards L., Schaefer-Solle N., Grant L., Ellingson K., Groom H., Zunie T., Thiese M., Ivacic L., Wesley M., Lamberte J., Sun X., Smith M., Phillips A., Groover K., Yoo Y., Gerald J., Brown R., Herring M., Joseph G., Beitel S., Morrill T., Mak J., Rivers P., Harris K., Hunt D., Arvay M., Kutty P., Fry A., and Gaglani M., 2021, Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - Eight U.S, Locations, December 2020-March 2021, Morbidity and Mortality Weekly Report, 70: 495-500.

https://doi.org/10.15585/mmwr.mm7013e3

PMid:33793460 PMCid:PMC8022879

Thompson, M., Natarajan K., Irving S., Rowley E., Griggs E., Gaglani M., Klein N., Grannis S., DeSilva M., Stenehjem E., Reese S., Dickerson M., Naleway A., Han J., Konatham D., Mcevoy C., Rao S., Dixon B., Dascomb K., Lewis N., Levy M., Patel P., Liao I., Kharbanda A., Barron M., Fadel W., Grisel N., Goddard K., Yang D., Wondimu M., Murthy K., Valvi N., Arndorfer J., Fireman B., Dunne M., Embí P., Azziz‐Baumgartner E., Zerbo O., Bozio C., Reynolds S., Ferdinands J., Williams J., Link-Gelles R., Schrag S., Verani J., Ball S., and Ong T., 2022, Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance - VISION network, 10 States, august 2021-january 2022, Morbidity and Mortality Weekly Report, 71: 139-145.

https://doi.org/10.15585/mmwr.mm7104e3

PMid:35085224 PMCid:PMC9351525

Thomas S., Moreira E., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J., Marc G., Polack F., Zerbini C., Bailey R., Swanson K., Xu X., Roychoudhury S., Koury K., Bouguermouh S., Kalina W., Cooper D., Frenck R., Hammitt L., Türeci Ö., Nell H., Schaefer A., Ünal S., Yang Q., Liberator P., Tresnan D., Mather S., Dormitzer P., Şahin U., Gruber W., and Jansen K., 2021, Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine through 6 months, The New England Journal of Medicine, 385: 1761-1773.

https://doi.org/10.1056/NEJMoa2110345

PMid:34525277 PMCid:PMC8461570

Wang Y., Zhang Z., Luo J., Han X., Wei Y., and Wei X., 2021, mRNA vaccine: a potential therapeutic strategy, Molecular Cancer, 20(1): 33.

https://doi.org/10.1186/s12943-021-01311-z

PMid:33593376 PMCid:PMC7884263

Wang Y., Zhang Y., Wu H., Huang L., Yu H., Xie Z., Zhang H., Zhang W., Chen X., Zhang H., Zhang H., Jia C., Xia S., and Wang S., 2021, Safety and immunogenicity of a quadrivalent inactivated subunit non-adjuvanted influenza vaccine: a randomized, double-blind, active-controlled phase 1 clinical trial., Vaccine, 39(29): 3871-3878.

https://doi.org/10.1016/j.vaccine.2021.05.070

PMid:34088505

Watanabe A., Kani R., Iwagami M., Takagi H., Yasuhara J., and Kuno T., 2023, Assessment of efficacy and safety of mRNA COVID-19 vaccines in children aged 5 to 11 years: a systematic review and meta-analysis., JAMA pediatrics, 177(4): 384-394.

https://doi.org/10.1001/jamapediatrics.2022.6243

PMid:36689319 PMCid:PMC9871947

Wu Z., Hu Y., Xu M., Chen Z., Yang W., Jiang Z., Li M., Jin H., Cui G., Chen P., Wang L., Zhao G., Ding Y., Zhao Y., and Yin W., 2021, Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial, The Lancet, Infectious Diseases, 21: 803-812.

https://doi.org/10.1016/S1473-3099(20)30987-7

PMid:33548194

Xia S., Zhang Y., Wang Y., Wang H., Yang Y., Gao G., Tan W., Wu G., Xu M., Lou Z., Huang W., Xu W., Huang B., Wang H., Wang W., Zhang W., Li N., Xie Z., Ding L., You W., Zhao Y., Yang X., Liu Y., Wang Q., Huang L., Yang Y., Xu G., Luo B., Wang W., Liu P., Guo W., and Yang X., 2020, Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial, The Lancet, Infectious Diseases, 21: 39-51.

https://doi.org/10.1016/S1473-3099(20)30831-8

PMid:33069281

Xu S., Yang K., Li R., and Zhang L., 2020, mRNA vaccine era-mechanisms, drug platform and clinical prospection, International Journal of Molecular Sciences, 21(18): 6582.

https://doi.org/10.3390/ijms21186582

PMid:32916818 PMCid:PMC7554980

Yang L., Tang L., Zhang M., and Liu C., 2022, Recent advances in the molecular design and delivery technology of mRNA for vaccination against infectious diseases, Frontiers in Immunology, 13: 896958.

https://doi.org/10.3389/fimmu.2022.896958

PMid:35928814 PMCid:PMC9345514

Zhang C., Maruggi G., Shan H., and Li J., 2019, Advances in mRNA vaccines for infectious diseases, Frontiers in Immunology, 10: 594.

https://doi.org/10.3389/fimmu.2019.00594

PMid:30972078 PMCid:PMC6446947

Zhang C., 2023, Revolutionizing vaccinology: the rise of mRNA vaccine, Theoretical and Natural Science, 21: 103-108.

https://doi.org/10.54254/2753-8818/21/20230839